Teachers Retirement System of The State of Kentucky Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Teachers Retirement System of The State of Kentucky purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 12,200 shares of the company's stock, valued at approximately $653,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Janux Therapeutics by 3,592.9% during the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after buying an additional 520,898 shares during the period. Franklin Resources Inc. raised its stake in shares of Janux Therapeutics by 2,519.6% during the fourth quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock worth $26,625,000 after buying an additional 478,304 shares during the last quarter. Pictet Asset Management Holding SA acquired a new position in Janux Therapeutics in the fourth quarter valued at approximately $20,602,000. Finally, Vanguard Group Inc. boosted its stake in Janux Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after acquiring an additional 288,402 shares during the last quarter. Institutional investors own 75.39% of the company's stock.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 10,002 shares of company stock valued at $348,203 in the last three months. 29.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on JANX shares. Wedbush restated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Trading Up 2.6 %

Shares of Janux Therapeutics stock traded up $0.83 during trading on Friday, reaching $32.88. The stock had a trading volume of 825,257 shares, compared to its average volume of 849,212. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -28.10 and a beta of 3.27. The stock has a fifty day moving average price of $29.80 and a two-hundred day moving average price of $42.70. Janux Therapeutics, Inc. has a 52 week low of $22.52 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.